Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas

References

1. 1.↵
   2. Vujovic S,
   3. Henderson S,
   4. Presneau N, et al

   . Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157–65 doi:10.1002/path.1969 pmid:16538613

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Salisbury JR,
   3. Deverell MH,
   4. Cookson MJ, et al

   . Three-dimensional reconstruction of human embryonic notochords: clue to the pathogenesis of chordoma. J Pathol 1993;171:59–62 doi:10.1002/path.1711710112 pmid:8229458

   CrossRefPubMed
3. 3.↵
   2. Choi KS,
   3. Cohn MJ,
   4. Harfe BD

   . Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn 2008;237:3953–58 doi:10.1002/dvdy.21805 pmid:19035356

   CrossRefPubMedWeb of Science
4. 4.↵
   2. McMaster ML,
   3. Goldstein AM,
   4. Bromley CM, et al

   . Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 2001;12:1–11 doi:10.1023/A:1008947301735 pmid:11227920

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Healey JH,
   3. Lane JM

   . Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 1989;20:417–26 pmid:2662114

   PubMedWeb of Science
6. 6.↵
   2. Chambers KJ,
   3. Lin DT,
   4. Meier J, et al

   . Incidence and survival patterns of cranial chordoma in the United States. Laryngoscope 2014;124:1097–102 doi:10.1002/lary.24420 pmid:24122844

   CrossRefPubMed
7. 7.↵
   2. Tzortzidis F,
   3. Elahi F,
   4. Wright D, et al

   . Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006;59:230–37 doi:10.1227/01.NEU.0000223441.51012.9D pmid:16883163

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Bergh P,
   3. Kindblom LG,
   4. Gunterberg B, et al

   . Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000;88:2122–34 pmid:10813725

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Chugh R,
   3. Tawbi H,
   4. Lucas DR, et al

   . Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344–50 doi:10.1634/theoncologist.12-11-1344 pmid:18055855

   Abstract/FREE Full Text
10. 10.↵
    2. Young VA,
    3. Curtis KM,
    4. Temple HT, et al

    . Characteristics and patterns of metastatic disease from chordoma. Sarcoma 2015;2015:517657 doi:10.1155/2015/517657 pmid:26843835

    CrossRefPubMed
11. 11.↵
    2. Heffelfinger MJ,
    3. Dahlin DC,
    4. MacCarty CS, et al

    . Chordomas and cartilaginous tumors at the skull base. Cancer 1973;32:410–20 pmid:4722921

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Rosenberg AE,
    3. Brown GA,
    4. Bhan AK, et al

    . Chondroid chordoma: a variant of chordoma—a morphologic and immunohistochemical study. Am J Clin Pathol 1994;101:36–41 doi:10.1093/ajcp/101.1.36 pmid:7506477

    CrossRefPubMed
13. 13.↵
    2. Safwat A,
    3. Nielsen OS,
    4. Jurik AG, et al

    . A retrospective clinicopathological study of 37 patients with chordoma: a Danish national series. Sarcoma 1997;1:161–65 doi:10.1080/13577149778254 pmid:18521219

    CrossRefPubMed
14. 14.↵
    2. Benk V,
    3. Liebsch NJ,
    4. Munzenrider JE, et al

    . Base of skull and cervical spine chordomas in children treated by high-dose irradiation. Int J Radiat Oncol Biol Phys 1995;31:577–81 doi:10.1016/0360-3016(94)00395-2 pmid:7852123

    CrossRefPubMed
15. 15.↵
    2. Berven S,
    3. Zurakowski D,
    4. Mankin HJ, et al

    . Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine (Phila Pa 1976) 2002;27:374–79 doi:10.1097/00007632-200202150-00010 pmid:11840103

    CrossRefPubMed
16. 16.↵
    2. Borba LA,
    3. Colli B,
    4. Al-Mefty O

    . Skull base chordomas. Neurosurgery Quarterly 2001;11:124–39 doi:10.1097/00013414-200106000-00005

    CrossRef
17. 17.↵
    2. Colli B,
    3. Al-Mefty O

    . Chordomas of the craniocervical junction: follow-up review and prognostic factors. J Neurosurg 2001;95:933–43 doi:10.3171/jns.2001.95.6.0933 pmid:11765837

    CrossRefPubMed
18. 18.↵
    2. Crockard HA,
    3. Steel T,
    4. Plowman N, et al

    . A multidisciplinary approach to skull base chordomas. J Neurosurg 2001;95:175–83 doi:10.3171/jns.2001.95.2.0175 pmid:11780885

    CrossRefPubMed
19. 19.↵
    2. Kaneko Y,
    3. Sato Y,
    4. Iwaki T, et al

    . Chordoma in early childhood: a clinicopathological study. Neurosurgery 1991;29:442–46 doi:10.1227/00006123-199109000-00019 pmid:1922714

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Wu Z,
    3. Zhang JT,
    4. Zhang LW, et al

    . Prognostic factors for long-term outcome of patients with surgical resection of skull base chordomas: 106 case review in one institution. Neurosurg Rev 2010;33:451–56 doi:10.1007/s10143-010-0273-6 pmid:20668904

    CrossRefPubMed
21. 21.↵
    2. Bohman LE,
    3. Koch M,
    4. Bailey RL, et al

    . Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis—a SEER analysis. World Neurosurg 2014;82:806–14 doi:10.1016/j.wneu.2014.07.005 pmid:25009165

    CrossRefPubMed
22. 22.↵
    2. Zou MX,
    3. Lv GH,
    4. Zhang QS, et al

    . Prognostic factors in skull base chordoma: a systematic literature review and meta-analysis. World Neurosurg 2018;109:307–27 doi:10.1016/j.wneu.2017.10.010 pmid:29045855

    CrossRefPubMed
23. 23.↵
    2. Zhai Y,
    3. Bai J,
    4. Gao H, et al

    . Clinical features and prognostic factors of children and adolescents with clival chordomas. World Neurosurg 2017;98:323–28 doi:10.1016/j.wneu.2016.11.015 pmid:27838423

    CrossRefPubMed
24. 24.↵
    2. Jian BJ,
    3. Bloch OG,
    4. Yang I, et al

    . Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol 2010;98:101–08 doi:10.1007/s11060-009-0068-1 pmid:19953297

    CrossRefPubMed
25. 25.↵
    2. Mitchell A,
    3. Scheithauer BW,
    4. Unni KK, et al

    . Chordoma and chondroid neoplasms of the spheno-occiput: an immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 1993;72:2943–49 pmid:7693324

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Dorfman HD,
    3. Czerniak B

    . Bone cancers. Cancer 1995;75(1 Suppl):203–10 pmid:8000997

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Forsyth PA,
    3. Cascino TL,
    4. Shaw EG, et al

    . Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993;78:741–47 doi:10.3171/jns.1993.78.5.0741 pmid:8468605

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Soo MY

    . Chordoma: review of clinicoradiological features and factors affecting survival. Australas Radiol 2001;45:427–34 doi:10.1046/j.1440-1673.2001.00950.x pmid:11903173

    CrossRefPubMed
29. 29.↵
    2. Thieblemont C,
    3. Biron P,
    4. Rocher F, et al

    . Prognostic factors in chordoma: role of postoperative radiotherapy. Eur J Cancer 1995;31A:2255–59 doi:10.1016/0959-8049(95)00458-0 pmid:8652252

    CrossRefPubMed
30. 30.↵
    2. Lang N,
    3. Su MY,
    4. Xing X, et al

    . Morphological and dynamic contrast enhanced MR imaging features for the differentiation of chordoma and giant cell tumors in the axial skeleton. J Magn Reson Imaging 2017;45:1068–75 doi:10.1002/jmri.25414 pmid:27490009

    CrossRefPubMed
31. 31.↵
    2. Si MJ,
    3. Wang CS,
    4. Ding XY, et al

    . Differentiation of primary chordoma, giant cell tumor and schwannoma of the sacrum by CT and MRI. Eur J Radiol 2013;82:2309–15 doi:10.1016/j.ejrad.2013.08.034 pmid:24035342

    CrossRefPubMed
32. 32.↵
    2. Tsuji T,
    3. Chiba K,
    4. Watanabe K, et al

    . Differentiation of spinal giant cell tumors from chordomas by using a scoring system. Eur J Orthop Surg Traumatol 2016;26:779–84 doi:10.1007/s00590-016-1819-2 pmid:27449029

    CrossRefPubMed
33. 33.↵
    2. Yeom KW,
    3. Lober RM,
    4. Mobley BC, et al

    . Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. AJNR Am J Neuroradiol 2013;34:1056–61 doi:10.3174/ajnr.A3333 pmid:23124635

    Abstract/FREE Full Text
34. 34.↵
    2. Pamir MN,
    3. Ozduman K

    . Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas. Eur J Radiol 2006;58:461–70 doi:10.1016/j.ejrad.2006.03.020 pmid:16631334

    CrossRefPubMed
35. 35.↵
    2. Erdem E,
    3. Angtuaco EC,
    4. Van Hemert R, et al

    . Comprehensive review of intracranial chordoma. Radiographics 2003;23:995–1009 doi:10.1148/rg.234025176 pmid:12853676

    CrossRefPubMed
36. 36.↵
    2. Tian K,
    3. Wang L,
    4. Ma J, et al

    . MR imaging grading system for skull base chordoma. AJNR Am J Neuroradiol 2017;38:1206–11 doi:10.3174/ajnr.A5152 pmid:28428207

    Abstract/FREE Full Text
37. 37.↵
    2. Pope WB,
    3. Sayre J,
    4. Perlina A, et al

    . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466–74 pmid:16286386

    Abstract/FREE Full Text
38. 38.↵
    2. Hilario A,
    3. Sepulveda JM,
    4. Perez-Nuñez A, et al

    . A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas. AJNR Am J Neuroradiol 2014;35:1096–102 doi:10.3174/ajnr.A3837 pmid:24457819

    Abstract/FREE Full Text
39. 39.↵
    2. Valles FE,
    3. Perez-Valles CL,
    4. Regalado S, et al

    . Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol 2013;34:35–40 doi:10.3174/ajnr.A3165 pmid:22936096

    Abstract/FREE Full Text
40. 40.↵
    2. Pope WB,
    3. Lai A,
    4. Mehta R, et al

    . Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882–89 doi:10.3174/ajnr.A2385 pmid:21330401

    Abstract/FREE Full Text